Clinical Study
Obinutuzumab: A Study Drug for Lupus Nephritis
Obinutuzumab is a study drug to reduce the B cells of lupus nephritis. The drug is currently approved for certain blood type cancers such as leukemia and lymphoma. However, scientists and doctors do not know the effectiveness of the treatment for patients with lupus nephritis. Research is needed to learn if the drug may be approved and used to improve the health of people suffering from lupus nephritis.
For more information contact:
Inge Stijleman
inge.stijleman@hsc.utah.edu
8012131368
IRB#: IRB_00145715
| PI: Josephine Abraham
| Department: NEPHROLOGY ADMINISTRATION
| Approval Date: 2022-07-27 06:00:00
Specialties: Nephrology & Hypertension
Who can participate?
Gender: All
Age: Under 7 or over 18 years old
Volunteers: Volunteers with special conditions
Location: In Person
Inclusion Criteria:
- Ages 18-75
- All genders
- In-person at University of Utah
- Time commitment approx. 3 years and continuing regular 6 months follow up visits
- Compensation $75 for each visit and travel costs
Exclusion Criteria:
- Pregnant or breastfeeding women
- Need for dialysis or renal transplantation
- HIV
- Turberculosis
Will I be paid for my time?
Yes